Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that utilize the ubiquitin proteasome system (UPS) to degrade proteins of interest (POI). PROTACs are potentially superior to conventional small molecule inhibitors (SMIs) because of their unique mechanism of action (MOA...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Hematol Oncol
Päätekijät: He, Yonghan, Khan, Sajid, Huo, Zhiguang, Lv, Dongwen, Zhang, Xuan, Liu, Xingui, Yuan, Yaxia, Hromas, Robert, Xu, Mingjiang, Zheng, Guangrong, Zhou, Daohong
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2020
Aiheet:
Review
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7384229/
https://ncbi.nlm.nih.gov/pubmed/32718354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00924-z
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia